Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

10 Apr 2018

Ayala Pharma, which launched in late 2017, has raised $17m via a series A financing round to propel its lead precision cancer therapy into Phase II – an asset it licensed from Bristol-Myers Squibb.

Israeli Flag in Jerusalem, israel — Emerging Israeli biopharma flies flag for ex-BMS cancer therapy

Ayala Pharma, an Israeli oncology company built around targeted cancer therapies licensed from Bristol-Myers Squibb Co., has raised $17m to take its lead asset into Phase II trials.

The emerging company, based in Rehovot, was founded in December 2017 and is backed by local investors Israeli Biotech Fund...